Back to All

Diaceutics wins award for IPO of the year at 2020 Small Cap Awards

29 June, 2020


Diaceutics PLC was awarded ‘IPO of the Year’ at the 8th Annual Small Cap Awards held virtually at an online ceremony on June 25th, 2020

The Small Cap Awards celebrate the achievements and performance of the best companies in the small and micro-cap business community (sub £200m market capitalisation) across 12 categories.

The event judging panel which consisted of high performing fund managers from a range of Venture Capital and Investment institutions from the City of London and beyond, held that:

“Diaceutics listed on AIM in March 2019, raising £17 million and the shares have since doubled in value. In what was a quiet year for IPOs, the judges were impressed by the strong operational performance and focussed growth strategy.”

Diaceutics’ strong performance comes as a result of the foresight shown in developing an increasingly deeper profile in the Precision Medicine diagnostics sector through the analysis and implementation of key data insights in the diagnostic testing field.  The company has also championed the creation of a global testing ecosystem by investing in a digital platform – DXRX – to enable the collaboration needed between all precision medicine stakeholders to get every patient the treatment they deserve.

Diaceutics has built strategic relationships with 36 of the world’s leading pharmaceutical clients and a growing network of 2500+ labs in 51 countries to improve the development and commercialization of precision medicine and companion diagnostics (CDx).

These relationships have enabled Diaceutics to work on every precision medicine ever brought to market, to benefit patients with life threatening diseases in both oncology and general medicine.  As a result of these efforts, Diaceutics has been working closely behind the scenes with multi-billion dollar pharmaceutical companies, assisting in the development of  companion diagnostics tests and commercialised drug therapies for a number of life threatening diseases and conditions.

It is the success in this arena that underpinned the success at the company’s IPO last year, making it one of only four IPO listings by a company with an office in Northern Ireland.

Philip White CFO at Diaceutics shared the news of the win and was quick to acknowledge the broader team effort behind it, saying:

Philip White

Philip White, CFO, Diaceutics: “The result reflects all our hard work and dedication so on behalf of the leadership team, I’d like to say a big thank you to everyone at Diaceutics.”

Other nominees in the category included Brickability Group, Essensys, Argentex Group PLC, Loungers and Pebble Group.

Full details of the awards, category recipients, previous winners and judging panels can be found here.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny